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Introduction 
Depression and anxiety are pretty common in patients with cancer, 30 to 40 % 
(Mitchell et al. 2011) of the patients express these symptoms, which are often lin-
ked with several problems like a decrease of quality life, non adherence to medical 
treatments, increased healthcare utilization, decrease of social function, increased 
sensitivity to pain, hopelessness, desire of dying, decreased survival rates, increa-
sed rates of suicide. (Arietta et al. 2014)

Antidepressant and benzodiazepine (less frequently) are usually used to treat these 
symptoms but the efficiency of these medicines is limited. (Ostuzzi et al. 2015) 
Benzodiazepine are mainly designed for a short term use, and have a negative be-
nefices/risks balance for a long term range treatment, involving addiction, tole-
rance, higher risk of overdosing, loss of memory and social function; (Ashton 
1986). Moreover, antidepressants never showed its superiority to placebo for trea-
ting cancer related distress (Ostuzzi et al., 2015)

A serotoninergic psychedelic substance, psilocybin (psilocyn) that is 5-HT2A re-
ceptors agonist (Vollenweider and Kometer, 2010) and induces various and impor-
tants modifications in perceptions, emotions and sensations (Halberstadt 2015) 
appear to be promising for treating cancer related depression and anxiety in va-
rious recent studies. Serotoninergic psychedelics has been tested for this purpose 
back in the 60s and 70s and the resulting studies suggested that theses molecules 
might be useful in treating distress for cancer patients, (Grof et al. 1973) but these 
studies probably does not stick to the actual research standards.

Unfortunately, the research about serotonin agonists psychedelics have been 
stopped  for many years in response to the wide-spread non medical use of these 
substances, until a few years ago. Which also caused a bad reputation towards 
these substances.

	 	 3
BAHI Camile, 2018
Very recently, some research institutes have taken back psychedelics research, 
and proved that this molecule has a well-established physiological and psycholo-
gical safety profile in human laboratory and clinical trial research (Johnson et al. 
2008), is not known to be addictive and may have anti-addictive properties (Ross, 
2012).

Heffter institute is the main organism leading studies about these substances and 
trials for treatment against anxiety and depression (mainly cancer related depres-
sion), and addiction.

This review aims to examine if a psilocybin based therapy could be considered for 
treating patients with cancer related depression and/or anxiety and more precisely 
if it can be considered as efficient and also safe for this purpose with the actual 
knowledge.

It also aims to sum up the work Heffter institute have accomplished until now on 
this particular subject, and eventually to get a better understanding about psycho-
logical and neurobiological mechanisms implicated in the anti depressant and an-
xiolytics action of psilocybin, if it is confirmed.

Method  
Realization of the review 
This systematic review is inspired by the PRISMA directives lines, according to the 
ISSM PRISMA checklist that can be found on https://www.elsevier.com/__data/
promis_misc/ISSM_PRISMA_Checklist.pdf

Ethical approval for this protocol and the planned systematic review was not requi-
red.

Searching process 
Since this review focuses on Heffter institute research works, the research proce-
dure consisted in reaching the organism database in the « cancer » section and 
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looking for the studies available which can be found on : https://heffter.org/study-
publications/. Further research have been reached on PubMed to august 2018, but 
no other relevant study met the inclusion criteria, with the keywords : psilocybin, 
depression, anxiety, cancer (together).

Selecting the studies  
The search returned 15 articles on Pubmed and 5 on the Heffter institute database. 
On the 20 articles, 4 met the inclusion criteria and have been analyzed in this sys-
tematic review.

Inclusion criteria included :  
- Being about the use of psilocybin for treating cancer related depressive and an-
xious states

- Including adult participants (18+ years old) with SCID (DSM-IV) diagnosis Ad-
justment disorder w/anxiety and/or depressed mood, chronic

- Being published in English language at the date of the 16 august 2018.

- Including at least 20 participants for the quantitative studies, 10 for the qualita-
tive ones

- Being randomized, blinded if quantitative study

Studies were excluded if they were not published in an English language peer-re-
viewed journal, or if they used others substances than psilocybin to treat depres-
sion and anxiety.

several comparisons of the studies have been done  to determine if  some were 
too similar in order to exclude those from the review. In the present case, none of 
these studies has been excluded.

Data have been extracted after multiple readings through piloted forms for quanti-
tative studies and independently for qualitative studies.
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Data extraction  
Extracted data included : author, year of publication, country, study design, sample 
size, percentage of women, type of cancer, stage, follow up, studied parameters, 
measurement tools, prior psychiatric conditions, Adverse events, Study design, 
Dosages, number of dosage sessions, occurrence of serious psychiatric adverse 
events and quantitative data for analysis.

Data has been manually extracted trough pre filled form using «apple’s 
Numbers » application for Mac OS.

Quality assessment  
The overall quality of the studies and the risk of biais has been assessed according 
Cochrane Risk of Bias Tool for Randomized Controlled Trials (Cochrane collabora-
tion, 2008) and the Jadad scale (Hempel et al. 2011) when it came to quantitative 
studies and to Critical Appraisal Skills Programme for qualitative studies when it 
came to qualitative studies (Critical Appraisal Skills Program, 2018 ), these tool 
provides guidance in order to evaluate the internal validity of the study and for 
translating this to risk of bias. Each study has been rated as being as good quality, 
fair quality and poor quality.

Performing a funnel plot analysis was not relevant according to the relatively re-
stricted amount of studies.

Results synthesis and outcomes :  
Data about depressed patients’s response to psilocybin, superiority from placebo 
at different periods of follow up on depression and anxiety,  psychiatric and medi-
cal safety, psychological and neurobiological supposed mechanisms, has been 
presented through a systematic narrative synthesis.
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A peto Odds ratio (statsdirect 2018) has been manually performed for a meta ana-
lysis and integrated into forest plots to compare the quantitative results exploited 
in the studies. These analyses were synthetized in separate tables.

Results  
Included studies   
20 articles were screened for this review. 
After reading the papers, excluding duplicates, 4 met the inclusion criteria, (see Fi-
gure 1 for flowchart).

2 of these articles (Ross et al. 2016, Griffiths et al. 2016) consisted in randomized 
double blind crossover quantitative studies with cancer patients, in one unique do-
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sage session of psilocybin as treatment for cancer related distress with a 6-month 
follow-up.

Both used a medium to high dose of psilocybin (0,3mg/kg and 30mg/70kg) and 
compared its effect to a placebo, niacin in the study conducted by Ross and col-
leagues, and a low dose of psilocybin (1mg/kg), considered as inactive, in the stu-
dy conducted by Griffiths and colleagues.

A total of 79 patient received psilocybin in these two studies.

2 studies (Belser et al. 2017, Swift et al. 2017) consisted in 13 qualitative interviews 
each about understanding the psychological mechanisms involved in a psilocybin 
session and getting a better understanding about it’s anti depressive and anxiolytic 
effect on cancer patients (interview were realized with participants coming from the 
first quantitative study, conducted by Ross and colleagues and included in this re-
view), 5 of the participants were interviewed within 1 week following their second 
psilocybin dosing session, and eight were interviewed approximately 1 year follo-
wing their session.

Characteristics of the available literature 
The extracted studies characteristics were presented in supplementary table 1 
(available page 31 and in a numeric format on demand).

Of the two quantitative studies, both studied similar parameters (systolic and dias-
tolic blood pressure, hearth rate, depression, anxiety, subjective drug effect, quali-
ty of life, sustaining of the effects, spirituality, spiritual well being)

Similar scales were also shared between these studies to analyze and quantify de-
pression and anxiety such as : Hospital Anxiety and Depression Scale (HADS), 
self-rated subscale of depression (HAD-D) (Snaith 2003),  Beck Depression Inven-
tory (BDI) (Beck 1961); Spielberger State-Trait Anxiety Inventory (STAI) (american 
psychological association 2018) self-report measure of state (STAI state or STAI S) 
and trait (STAI trait or STAI T) anxiety… (Griffiths et al. 2016, Ross et al.2016)
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The second study, conducted by Griffiths and colleagues used several more scales 
to quantify some more precise secondary outcomes, as mystical experience for 
example, for further details, please refer to supplementary table 1. 

The two qualitative studies focused on getting a better comprehension of the psy-
chological mechanisms underlying the anxiolytic and anti-depressant effects of 
psilocybin.  
For this purpose, interviews were piloted by an interpretative Phenomenological 
Analysis (IPA) (Smith and Osborn 2007), consisting in “a qualitative research ap-
proach committed to the examination of how people make sense of their major life 
experiences”. (Belser et al. 2017, Swift et al. 2017)

This questionnaire included question about meaningful visuals, emotions, wisdom 
lessons, psychological distress, feeling of interconnectedness, letting go, shift in 
perspectives toward cancer recurrence or progression… (Belser et al 2017. Swift 
et al. 2017)

Participant and clinical features of samples in included studies 
The 4 studies included a total of 105 randomized participants, with the number of 
randomized participants varying from 13 to 51, there was slightly more women 
overall (66%). The mean age across the studies was approximately 56 and the 
ages within the studies, when it was available, varied from 22 to 75.

Psychiatric conditions were analyzed thanks to DSM-IV (Bell, 1994) in all studies, 
and before the first session, a total of 76 participants presented an SCID (DSM-IV) 
diagnosis Adjustment disorder with anxiety and depressed mood, chronic Or SCID 
(DSM-IV) diagnosis Adjustment disorder with anxiety, chronic. 5 participants pre-
sented a diagnosis of dysthymic disorder, 8 with generalized anxiety disorder 
(GAD), 14 with major depressive disorder (MDD) , 4 participants presented a dual 
diagnosis of GAD with MDD and 1 participant was diagnosed a GAD and dysthy-
mic disorder. (Ross et al. 2016, Griffiths et al. 2016, Belser et al. 2017, Swift et al. 
2017)
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Medication Status 
In both quantitative studies, none of the participants were under any psychotropic 
substance at the time of the studies enrollment.

Approximately 55% of the participants had been under anti-depressant or anxioly-
tic medication prior the overall studies. (Ross et al 2016. Griffiths et al. 2016)

Risk of Biais within the included studies  
Quantitative Studies were appraised using Cochrane Risk of Bias Tool for Rando-
mized Controlled Trials and Jadad scale, complete results are available in table 1 
and 2.

Both studies obtained 4 out of 5 points at the Jadad scale which is qualified as ri-
gorous and filled all items of the Cochrane’s checklist (Cochrane collaboration ,
2008), but 1 uncertain concerning the blinding method for the study conducted by 
Ross and colleagues.

According to the scores obtained using these 2 tools , both studies obtain a 
« good quality » ranking and appear to have a low risk of biais.

Qualitative studies where appraised using Critical Appraisal Skills Program for qua-
litative studies (CASP, 2018) and met all criteria. According to this tool, the studies 
are ranked as « good quality studies » with a low risk of biais (more detail in table 
3).
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Table 2. Jadad scale
Was the study 
described as 
randomized ?
Was the study 
described as 
double blind ? 
Was there a 
description of 
Withdrawals 
and dropouts ?
Optional points
Study 1 : Ross et 
al.
Yes Yes Yes Method of blinding 
explained and ap-
propriated
Study 2 : Griffiths 
et al.
Yes Yes Yes Method of blinding 
explained and ap-
propriated
BAHI Camile, 2018
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Study Results   
Depression  
The two quantitative studies evaluated psilocybin as potential treatment for de-
pression in patients with cancer (Ross et al. 2016, Griffiths et al. 2016).

The first study, a randomized double-blind trial, was conducted by Ross and col-
leagues and placed 28 participants to receive Psilocybin or placebo (niacin), for 
one single session each.

Depression was evaluated using multiple depression scales (more details in sup-
plementary table 1), and  they concluded that there were significant differences 
between the experimental and control groups. Psilocybin produced immediate and 
enduring anti-depressant response rates, as well as significant anti-depressant 
remission rates. For example, 7 weeks after dose 1, 83% of participants in the psi-
locybin first group (vs. 14% in the niacin first group) met criteria for anti-depressant 
response (with the BDI), (Ross et al. 2016).

The 6,5-months follow-up (after both groups received psilocybin) also showed 
great results, anti-depressant response rates were approximately 60–80% (Ross et 
all. 2016).

The second study, conducted by Griffiths and colleagues, which was also a ran-
domized double-blind trial, enrolled 51 adults and compared a High dose of psilo-
cybin (30mg/70kg and 20mg/70kg) to a low dose of the same drug, considered as 
inactive (3 and 1 mg/70kg).

The investigators also used multiple scales to assess the efficiency of psilocybin 
on depression such as GRID-HAM-D17 (details in supplementary table 1).

Results also assessed that Psilocybin was efficient to treat depression.
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They found out that rates of clinically significant response and symptom remission 
of depression (GRID-HAMD-17) showed large effects of psilocybin that were sus-
tained at 6 months.

For instance, 5 weeks after Session 1, 92% of participants in the High-Dose-1st 
Group showed a clinically significant response, compared with a 32% response 
rate in the Low-Dose-1st Group, at 6 months 79% of those in the High-Dose-1st 
Group continued to show a clinically significant response. (Griffiths et al. 2016)

the overall rate of symptom remissions at 6 months for all participants was 65%, 
which is also significant.

Meta analysis of the results :

We performed a Peto odds ratio with the extracted results at 5 to 7 weeks post 
dose 1 (depending the study) in order to examine response rates to the treatment 
but also remission rates for both studies (the results are exposed in table 4 and fi-
gure 2 and 3), we also combined these results, putting together the results obtai-
ned at the HADS-D scale from the study conducted by Ross et al. and at the 
GRID-HAM-D scale from the study conducted by Griffiths and colleagues, to eva-
luate psilocybin efficiency for depression across the studies.   

Table 4. Peto odds ratio results for depression 5 to 7 weeks after dose 1
Depression appre-
ciation tool
OR (peto odds 
ratio)
CI (confiance in-
terval)
V (Weight)
Study 1 : Ross et al. BDI response rate 0.069 [0.057; 0.084] V =1.813
HADS-D response 
rate
0.311 [0.257; 0.375] V=1.797
BDI-Remission 0.096 [0.080; 0.117] V=1.797
HADS-D Remission 0.099 [0.082; 0.119] V=1.815
Study 2 : Griffiths 
et al.
GRID-HAM-D res-
ponse rate
0.099 [0.086; 0.114] V=3.029
GRID-HAM-D Remis-
sion
0.196 [0.170; 0.226] V=3.130
Combined results. Total Depression 
response rate
0.149 [0.133; 0.167] V=4.792
Total Remission for 
depression
0.152 [0.136; 0.169] V=4.923
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Response 
Peto Odds performed on both studies showed an obvious superiority of psilocybin 
over placebo for Response rates to the treatment for depression.

Remission
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Peto Odds performed on both studies showed also a significant superiority of psi-
locybin over placebo for Remission to depression following the treatment.

Combined results assesses that superiority from psilocybin over placebo.

Anxiety 
The two quantitative studies also evaluated psilocybin as a treatment for cancer 
related anxiety (Ross et al. 2016, Griffiths et al. 2016).

The first study, a randomized double-blind trial, supervised by Ross and col-
leagues, placed 28 participants to receive Psilocybin or placebo (niacin), for one 
single session each.

Anxiety was evaluated using multiple Anxiety evaluation scales (more details in 
supplementary table 1), and concluded that the psilocybin group (compared to the 
active control) demonstrated immediate, substantial, and sustained (up to 7 weeks 
post-dosing) clinical benefits in terms of reduction of anxiety.

These reductions remained significant at approximately 8 months, post-psilocybin 
dosing. (Ross et al. 2016).

The second study, conducted by Griffiths and colleagues,  was also a randomized, 
double-blind trial, enrolled 51 adults and compared a High dose of psilocybin 
(30mg/70kg and 20mg/70kg) to a low dose of the same drug, considered as inac-
tive (3 and 1 mg/70kg). (Griffiths et al. 2016).

The investigators also used multiple scales to assess the efficiency of psilocybin 
on Anxiety such as GRID-HAM A (more details in supplementary table 1).

Rates of clinically significant response and anxiety symptoms remission showed 
large effects of psilocybin that were sustained at 6 months. (Griffiths et al. 2016).
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Meta analysis of the results : 
A peto odds ratio of the extracted results obtained at 5 or 7 weeks (depending on 
study follow up) post dose 1 was performed in order to examine response rates to 
the treatment but also remission rates for both studies (results are exposed in table 
5 and figure 4), we also combined the results, putting together the results obtained 
for the HADS-A scale from the study conducted by Ross and colleagues and for 
the GRID-HAM-A scale from the study conducted by Griffiths and colleagues to 
evaluate psilocybin efficiency on anxiety across the studies.

Table 5. Peto odds ratio results for Anxiety 5 to 7 weeks after dose 1
Anxiety appre-
ciation tool
OR (peto odds 
ratio)
CI (confiance interval) V (weight)
Study 1 :Ross et 
al.
HADS-A response 
rate
0.159 [0.131;0.192] V=1.672
Study 2 : Grif-
fiths et al.
GRID-HAM-A 
response rate
0.141 [0.122;0.162] V=3.249
GRID-HAM-A 
Remission
0.180 [0.156;0.207] V=2.972
Combined re-
sults
Total Anxiety 
response rate 
0.148 [0.132;0.165] V=4.956
	 	 17
BAHI Camile, 2018
Response 
Peto Odds performed on both studies showed a significant superiority of psilocy-
bin over placebo for Response rates to the treatment for anxiety.

Remission  
As data for anxiety remission could not been obtained for the study conducted by 
Ross and Colleagues, we were not able to perform forest plot of the Peto odds ra-
tio across the two studies. 

It is important to note that the study conducted by Griffiths and colleagues 
concluded on a superiority of psilocybin over placebo for remission rates too.

Psychiatric safety of use 
The study conducted by Ross and Colleague found out that there were no serious 
Adverse events, either medical or psychiatric, in the trial that were attributed to ei-
ther psilocybin or niacin. No pharmacological interventions (as benzodiazepines or 
anti-psychotics) were needed during dosing sessions, no participants abused or 
became addicted to psilocybin, there were no cases of prolonged psychosis or 
	 	 18
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hallucinogen persisting perceptual disorder (HPPD) and no participants required 
psychiatric hospitalization.

They also noted that the most common psychiatric adverse events were transient 
anxiety (17%) and transient psychotic-like symptoms (7%: one case of transient 
paranoid ideation and one case of transient thought disorder), attributable to psilo-
cybin and are all known adverse events of psilocybin, were transient, tolerable and 
consistent with previous research (Ross et al. 2016).

The second study, conducted by Griffiths and colleagues, determined that tran-
sient episodes of psychological distress during psilocybin sessions were more 
common after the high dose than the low dose. 

They described occurrence of Psychological discomfort in 32% of participants in 
the high-dose session and 12% in the low-dose session. An episode of anxiety 
occurred in 26% of participants in the high-dose session and 15% in the low-dose 
session. One participant had a transient episode of paranoid ideation (in the high 
dose session) . There were no cases of hallucinogen persisting perception disorder 
or prolonged psychosis (Griffiths et al. 2016).

According to these results, psilocybin seems to be clinically safe for administration 
for cancer patients, in a supervised environment, on a psychiatric point of view.

Medical safety 
The first study, conducted by Ross and colleague, concluded that there were no 
serious adverse cardiac events.

They noted that the medical AEs (non-clinically significant elevations in blood 
pressure and Hearth rate, headaches, nausea) attributable to psilocybin were all 
known AEs of psilocybin, were transient and tolerable (Ross et al. 2016).

Later, the study supervised by Griffiths assumed that no serious adverse events 
attributed to psilocybin administration occurred.
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A number of adverse events occurred during psilocybin sessions, none of which 
were deemed to be serious. All of these adverse events had resolved fully by the 
end of the sessions. 

They noted that there were transient moderate increases in systolic and/or diasto-
lic blood pressure after psilocybin. An episode of elevated systolic blood pressure 
occurred in 34% of participants in the high-dose session and 17% of participants 
in the low-dose session. An episode of elevated diastolic blood pressure occurred 
in 13% of participants in the high-dose session and 2% of participants in the low 
dose session, None of these episodes needed medical intervention. 

Nausea or vomiting occurred in 15% of participants in the high-dose session and 
none in the low-dose session. 

An episode of physical discomfort occurred in 21% of participants in the high-
dose session and 8% in the low-dose session.  (Griffiths et al. 2016)

According to these results we can assess that psilocybin seems to be safe to ad-
minister to cancer patients, in a supervised environment, on a medical point of 
view.

Psychological mechanisms 
The qualitative studies that were analyzed in this review focused on getting a bet-
ter understanding of the psychological mechanisms, involved in a psilocybin the-
rapy for depressive and anxious patients with cancer, and in depressive and an-
xious patients more globally.

The study conducted by Belser’s team deducted that the psilocybin experience 
may be conceived as relationally embedded : indeed, the most common thematics 
evoked by participants were : forgiveness of others, loved ones as spirit guides, 
the importance of narrating one’s experience with loved ones, and improved rela-
tionships posttreatment. 
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Nearly all participants reported having an experience of love and joy, though these 
exalted experiences arose primarily through a specific human relationship with 
another person, whether it was a parent, child, or partner (Belser et al. 2017).

Moreover, the findings of this study also suggest that embodiment, was a critical 
feature of participant experiences. (Belser et al. 2017)

Beside that, as slightly more than a half of participants experienced fear or anxiety 
during the sessions, they found out that transient periods of distress, even intense 
experiences of fear and panic, can be well tolerated by study participants in a 
supportive therapeutic milieu.

Both participants and the research team came to understand these difficult expe-
riences as part of a necessary and ultimately beneficial process, they said.

These results also indicates that psilocybin occasioned a vast range of emotions, 
suggesting that participants may emerge from this treatment having experienced 
profound emotional depths and expanded affective boundaries (Belser et al. 2017).

Most of participants have experienced complexe closed eyes visuals, it seems that 
those may have served as principle organizing motifs of subjective experience with 
multifold vectors (e.g., audiovisual, relational, autobiographical, spiritual, epistemo-
logical, ontological). (Belser et al. 2017)

Finally, Belser and colleagues reported that participants described lasting impacts 
to their quality of life, life priorities, and their sense of identity, participants descri-
bed feeling “reborn,” more confident, more connected, and more alive. They  also 
described a feeling of empowerment and being “unstuck,” with resulting healthier 
behaviors. (Belser et al. 2017).

The second study, supervised by Swift and colleagues, revealed that experiential 
and immersive quality of the psilocybin therapy may help explain the immediate 
and enduring positive changes in participant’s lives after a single session.

They noted that the sessions brought new perspectives to participants regarding 
their cancer and the way they experiences it, reporting that participants were able 
to more clearly consider the reality of cancer and death in their lives, and consis-
tently reported no longer being preoccupied or overwhelmed by fear.
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Swift and colleagues assessed that the mechanism behind the psilocybin sessions 
may not be apprehended like classical antidepressant or anxiolytic drugs, the re-
sults showed that following their psilocybin session, participants did not merely re-
turn to the level of functioning that existed prior to their cancer diagnosis, but ra-
ther nurtured a heightened sense of meaning and perspective in their lives. (Swift 
et al. 2017)

These studies suggests that Psylocybin can bring truly immersive and meaningful 
mystical experiences, sometimes leading participants to face their fears and 
change perspectives on something that has caused their psychological distress, 
making them able again to interact with others and with life in general.

This way, people learn how to live with their new condition, to accept it and even-
tually to use it to sublime and give a new sense to their life.

Neurobiological mechanisms  
The study conducted by Ross and colleagues, considered the existing literature to 
explore neurobiological mechanisms involved in the action of psilocybin :

Those are apparently linked to the 5HT2A binding effects of Psilocybin (as well as 
others psychedelics (serotoninergic hallucinogens), and more precisely, 5HT2A 
downregulation may explain some of the rapid and sustained anxiolytic effects of 
psilocybin.

Indeed, they reported that cortical 5HT2A receptor expression is increased in 
postmortem samples of patients with depression who display suicidality.

This study also suggest that the glutamate system may explain some of the anti-
depressant effects of psilocybin : In rodents, serotoninergic psychedelics enhance 
cortical glutamatergic transmission, especially in the medial PFC, and increase ac-
tivation of cortical α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptors (Aghajanian and Marek, 1997) as well as BNDF.

In parallel, cortical AMPA activation is known to stimulate the expression of cortical 
BDNF (associated with neuronal growth, differentiation and synaptogenesis) (Hsu 
et al. 2015) and decreased cortical BDNF is associated with major depression in 
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humans (Duman. 2004). Also, cortical BDNF normalizes with anti-depressant 
treatment (Shimizu et al. 2003). 

Moreover, neuroimaging research with psilocybin is beginning to suggest potential 
anti-depressant mechanisms of action at the level of brain structure activity and 
network connectivity, they said.

Task-free functional magnetic resonance imaging research in normal volunteers 
under the influence of psilocybin has demonstrated decreased activity in the me-
dial PFC and decreased connectivity within the default mode network (DMN) (Ca-
rhart-Harris et al. 2012, 2014), beside that, depressive symptoms have been asso-
ciated with increased activity in the medial PFC (Farb et al. 2011) and normaliza-
tion of medial PFC activity has been demonstrated with anti-depressant treatment 
(Holtzheimer and Mayberg, 2011), Patients with major depression (compared to 
controls) also demonstrated increased DMN connectivity (Berman et al. 2011), they 
said.

Complexe neurobiological mechanisms are involved in psilocybin action and are 
yet to be established. This may help to better understand brain connectivity and 
depression or anxiety mechanisms. The Glutamatergic system as well as the acti-
vity modulation in the DMN seems to represent some promising key mechanisms. 

Discussion 
This systematic review and meta-analysis revealed the beginning of a promising 
new approach about how to treat cancer related distress, and maybe even more, 
anxiety and depression in a more general way. 

Since this review focuses on a really innovative approach, it is the first to be reali-
zed about the subject. 

For the same reason, the number of studies included was relatively limited : in-
deed, we were able to include only 4 studies comprising 105 participants, synthe-
sizing data about 6 different themes. Psilocybin seemed to have a real potential for 
mental healthcare.
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Regarding to the results, this review might open minds about psilocybin and more 
widely, psychedelics (serotoninergic hallucinogens), that inherited a sulfurous repu-
tation since the 70’s and help to bring interest about these substance, that may 
completely renew the way we approach mental illness and it’s treatment, by it’s 
very specific action mechanism, both on a psychological and neurobiological point 
of view. These kind of therapies may improve quality of life of many distressed 
people, as cancer patients.

This review also underline the ambitious and passionate work Heffter institute 
achieved and continue to realize, about psychedelics for mental healthcare.

Main findings : potential use for depression and anxiety in cancer pa-
tients. 
The results exposed in this review showed that psilocybin appear to be effective as 
a treatment for depression and anxiety, obtaining significant results on multiple 
and recognized depression and anxiety measuring tools, performed meta analysis 
(which consisted in a Peto odds ratio) also concluded a significant superiority of a 
single psilocybin session over placebo for both depression and anxiety, as no 
classical anti-depressant ever reached this level of proof for treating cancer related 
distress. (Ostuzzi et al. 2015)

The remission rates were also significant for anxiety and depression on different 
scales such as BDI, HADS-D and GRID-HAM-D and GRID-HAM A.

Moreover, for one single session, the results sustained at least 6-months post ses-
sion for 60 to 80 % of patients overall. 

Regarding these results Psilocybin seems to be surprisingly efficient for treating 
cancer related depression and anxiety.

Numerous recents studies also showed great results for others use, as : addiction 
caring, PTSD, depression and anxiety in non cancerous patient and a great part of 
it were conducted by the Heffter institute.
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Safety of use 
 

Globally, no serious adverse events have been reported across the studies, on a 
psychiatric point of view as well as a medical one, these results seems to indicates 
that psilocybin is safe to use in a medically supervised environment, even for sen-
sible patients like cancer patients, the results were consistent to prior research on 
healthy volunteers and cancer patients, but the relatively limited size of the sample 
included in this review, underlines the fact that it has to be confirmed on larger po-
pulations. It is to know that very recents studies focusing on the safety with larger 
samples confirmed these results, that the Global Drug survey of 2017 designed it 
as the safest of any recreative drug (Winstock et al. 2017) and that the FDA recent-
ly approved psilocybin for a wider, phase 2b trial including on 216 participants 
across North America and Europe (Compass pathways. 2018), which is really en-
couraging.

Psychological and Neurobiological mechanism 
This review can’t conclude on a precise psychological or neurobiological mecha-
nism involved in the Psilocybin mode of action, but the results demonstrated com-
plexe and previously unthanked mechanisms, both on a psychological and neuro-
biological point of view.

Indeed, learning more about those, could bring a better knowing of general mental 
health, mechanisms of certain mental diseases like depression, anxiety, distress 
relating to end of life, and more generally, overall consciousness function. 

This way, it could also help to enhance psychological therapies and the way we 
care cancer patients and mental illnesses in general.

Thanks to psilocybin, patients don’t return to the state they have been prior their 
cancer, but learn to cope with it and to change their perspective toward cancer, 
accepting it and subliming it, to get new aims in life as well as a need of reconnec-
tion to others, their family, etc.
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Psilocybin seems to make patient face their fear and the reality of what they try to 
avoid, sometimes triggering challenging experiences, but experiences that serve 
as a support of their personnal sublimation or accomplishment. Those moments 
seems to represent an occasion to mature and grow-up off their difficulties, accor-
ding to participants. 

On a neurobiological point of view, research on the subject seems to indicates that 
the anti depressive effect of psilocybin may be related to it’s aptitude to  provoke 
5HT2A receptors down-regulation, enhancements of glutamatergic transmission in 
the medial PFC that trigger α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) activation, which stimulate BDNF production (as a decrease is asso-
ciated with depression in human). Neuroimaging reported a normalized medial 
PFC activity (hyperactive region in depressed patients) and a decreased DMN (de-
fault mode network) activity, while it was increased in depressed patients.

Psilocybin seems to share some neurobiological aspects with classical antidepres-
sants, but also many differences both on a psychological and neurobiological point 
of view. These mechanisms are still to investigate and not well known or unders-
tood, but these elements are encouraging and may represent some new key me-
chanisms to explore and the constant development in neurobiology and neuroima-
ging as well as the growing knowledge in psychology, should bring some further 
evidences, ideas and reflection about the topic.

Strengths and Limitations  
This comprehensive systematic review includes a global look around Psilocybin 
therapy, focusing on both quantitative aspects (with a serie of exploratory meta-
analysis about the efficiency of this serotoninergic psychedelic on cancer related 
distress (that were examined through the scope of multiple depression and anxiety 
appreciation tools)), and qualitative aspects (with the narrative analysis of qualita-
tive studies about the psychological mechanisms underlaying those therapeutical 
effects).
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This review also sums-up and bring the lights on the significant effort and implica-
tions put by Heffter institute in research about Psilocybin based therapies and 
more widely, psychedelic therapies for mental healthcare. Those topics have, for 
sure, a promising future.

Notwithstanding this, there are several limitations and results should be interpreted 
with some caution.

First of all, this review includes a relatively limited amount of studies, with a relati-
vely limited amount of participants, in this regard, the findings should be reevalua-
ted when more studies including wider populations will be released. 

Most of the patients were Caucasian and highly educated, which may influence the 
experiences participants lived during the session and decrease the overall genera-
lizability.

The strength of the findings exposed in this review result on the high quality of the 
studies and the apparent low risk of bias using tools like Cochrane Risk of Bias 
Tool for Randomized Controlled Trials, Jadad scale and Critical Appraisal Skills 
Program for qualitative studies.

Another limitation is that the meta analysis regrouped results that were obtained 
through different depression and anxiety scales, the appreciation criteria that 
constitute those scales are not exactly the same. In other hands, the choice of 
using a Peto odds ratio method was judicious because the participants groups 
were balanced in size, but since the difference from placebo revealed to be very 
significant, it may have exaggerated the results slightly.

Also, this study does not really take in account the psychotherapies sessions  oc-
curring before, during and after the sessions, that are an essential component of 
the patient care. 

Regarding the supposed psychological action mechanism of psilocybin, it is very 
complementary with those type of therapies (psychotherapy), certainly participa-
ting to the really encouraging results.

The crossover between psilocybin and placebo groups after 5 weeks may also in-
fluence the results at the 6 months follow-up, specifically for the low dose session.
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Conclusion and future implications 
Through this review, we discovered that Psilocybin seemed to be safe and really 
effective for treating cancer related depression and anxiety, even with one single 
dosing session. 

Moreover, it has uncovered that the mechanisms responsible of the anti-depres-
sant and anxiety effect are obviously very particular and seems to change people’s 
perceptions, leading them to acceptance and to integrate their struggles into so-
mething « useful » for their lives, instead of negatively searching to get rid of it, to 
avoid it, Fearing it.

The immersive and sometimes challenging experiences appear to serve as a vec-
tor of integration to the knowledge participants received during the session, which 
is often described as « beyond words ». (Belser et al. 2017)

On the other hand, no persisting or serious psychiatric adverse event has been si-
gnaled among the studies. 

Apparently, challenging experiences should be appreciated as a potentially useful 
and sometime necessary part of the experience. This underlines the importance of 
a supervised environment and the integration of psychotherapy sessions to opti-
mize the results.

 

Beyond the necessity to verify the reproducibility of these results on larger popula-
tions, the question of it’s efficiency for depression and anxiety in healthy and non 
hospitalized participants, and the question of how to organize supervised sessions 
and follow-up with these type of ambulatory participants may be reached.

Microdosing with repeated dosing sessions, appear to bring promising results in 
some recents studies, avoiding the challenging side of the experience, which 
might bring some autonomy to the patients, for this kind of therapy.

In other hand neurobiological mechanisms are still to precise and certainly hide 
some revelations about mechanisms involved in depression, consciousness and 
spirituality.
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Abstract
Background : 
Depression and anxiety are common in patients with cancer, classical antidepressant and anxiolytics has no 
proven efficacy on this type of distress compared to placebo. A Psilocybin (serotoninergic hallucinogen) 
based therapy appear to give promising results among some recent studies.

Aims :  
To examine if a psilocybin based therapy could be considered for patients with cancer related depression 
and/or anxiety and it’s safety.

To sum Heffter’s institute work, as the main research institute working on this topic.

Method :  
Following PRISMA a guidelines, a systematic review was conducted, for quantitative and qualitative studies 
about psilocybin for treating cancer related depression and anxiety. Pubmed and the Heffter institute data-
base has been reached for this purpose, separating studies in types : qualitative or quantitative. We studied 
the effects on cancer related depression and anxiety separately and investigated the psychological and 
neurobiological mechanisms.

Results : 
The 4 studies included a total of 105 randomized participants, meta analysis on depression and anxiety with 
pooled Peto odds ratio showed a significant superiority of psilocyfbin over placebo. The substance appea-
red to be safe for this type of patients. Surprising psychological mechanisms hypothesis have been found 
out.

Conclusions : 
Psilocybin appear to be potentially useful as treatment for cancer related depression and anxiety. Future 
research should verify these findings on wider populations and  eventually seek a way to apply this therapy 
to non hospitalized patient. 

Keywords : 

psilocybin, depression, anxiety, review, meta-analysis

Contexte :

La dépression et l'anxiété sont fréquentes chez les patients cancéreux, les antidépresseurs classiques et 
les anxiolytiques n'ont pas prouvé leur efficacité sur ce type de détresse par rapport au placebo. Une thé-
rapie basée sur la psilocybine (hallucinogène sérotoninergique) semble donner des résultats prometteurs 
parmi certaines études récentes.

Objectifs: 
examiner si un traitement à base de psilocybine pourrait être envisagé chez les patients souffrant de dé-
pression et / ou d’anxiété liée au cancer et si il peut être utilisé en toute sécurité, Mais également  de résu-
mer le travail de l'institut Heffter, en tant que principal institut de recherche travaillant sur ce sujet.

Méthode : 
En se référant aux lignes directrices PRISMA (Preferred Reporting Items for Systematic reviews and Meta-
analyses), une étude systématique a été menée, pour les études quantitatives et qualitatives sur la psilocy-
bine dans le traitement de la dépression et de l'anxiété liées au cancer. Pubmed et la base de données de 
l'institut Heffter ont été consultés à cette fin, en séparant les études par types : qualitative ou quantitative. 
Nous avons étudié les effets sur la dépression et sur l'anxiété liées au cancer séparément et ainsi que les 
mécanismes psychologiques et neurobiologiques.

Résultats : 
Les 4 études on inclus un total de 105 participants randomisés, une méta-analyse sur la dépression et l'an-
xiété grace a un Peto odds ratio combiné a montré une supériorité significative de la psilocybine par rap-
port au placebo. La substance semble également sans danger pour ce type de patients. Des hypothèses 
de mécanismes psychologiques inattendues ont été découvertes.

Conclusions: 
La psilocybine semble potentiellement utile comme traitement contre la dépression et l’anxiété liées au 
cancer. Les futures recherches devraient vérifier ces résultats sur des populations plus larges et éventuel-
lement chercher un moyen d'appliquer cette thérapie à des patients non hospitalisés.

Mots clés : 
psilocybine, dépression, anxiété, revue de literature, méta-analyse.
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